Pliant Therapeutics, Inc. (PLRX)
| Previous Close | 12.43 |
| Open | 12.42 |
| Bid | 12.19 x 100 |
| Ask | 12.62 x 100 |
| Day's Range | 12.26 - 12.43 |
| 52 Week Range | 10.22 - 19.62 |
| Volume | |
| Avg. Volume | 386,706 |
| Market Cap | 751.542M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.18 |
GlobeNewswirePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. “A highlight to this quarter’s progress wa
- GlobeNewswire
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time at the Lotte New York Palace Hotel in New York, New York. Interested parties may access the live webcast of the fireside chat by visiting the Investor Relations’ Events &
